Affini-T key facts
- Operator of a precision immunotherapy company intended to target core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors.
- It has raised $317.6M; the latest was Early Stage VC ($17.6M) in Oct 2024.
- Notable investors include Service Provider Capital, Olive Tree Capital, Catalio Capital Management, Spur Capital Partners, Ascent Equity Partners — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Affini-T
15+- ·The complete investor list: 15 names
- ·Watch Affini-T: the Monday email on marks, rounds and moves
Affini-T funding rounds
No funding rounds for Affini-T are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Affini-T investors
15 investors are on record for Affini-T, including Service Provider Capital, Olive Tree Capital, Catalio Capital Management and Spur Capital Partners. By type, the record holds 3 venture capital firms, 1 family office and 1 fund of funds.
About Affini-T
Operator of a precision immunotherapy company intended to target core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. The company specializes in identifying T-cell receptors against targets like KRAS and TP53 that are fundamental to tumor biology and leverages synthetic biology, enabling medical researchers to deliver therapies for patients with pancreatic, colorectal, and lung cancers.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2020
- Employees
- 88
- Website
- affinittx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Affini-T doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.